Translational Development Acquisition Corp.
TDAC TDACU TDACWCIK 0001926599 · Blank Checks · Nasdaq, Nasdaq, Nasdaq
Revenue (TTM)
—
Q1 Mar 2026
Net Income (TTM)
$6.1M
+9,059.7% YoY
Q1 Mar 2026
EPS Diluted (TTM)
—
Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
—
Q1 Mar 2026
Net Margin
—
Q1 Mar 2026
Free Cash Flow (TTM)
—
Q1 Mar 2026
Cash
$24.63K
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
0 sh
Q1 Mar 2026
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.
Balance Sheet
Cash vs Debt
Latest news
All news →-
High Neutral
TDAC Extends SPAC Deadline to June 2027 in Trust Amendment
Translational Development Acquisition Corp. shareholders approved up to 12 one-month extensions, giving the blank-check company until June 24, 2027 to complete...